Jennifer Good is the President and Chief Executive Officer of Trevi Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for chronic cough and other debilitating conditions. With more than 25 years of experience in the pharmaceutical industry, she has built a distinguished career focused on commercial strategy, product launches, and leadership in gastroenterology and neurology. Her expertise has consistently driven revenue growth and successful market entries for novel treatments targeting unmet patient needs. Prior to Trevi, Ms. Good served as President and CEO of Synergy Pharmaceuticals, where she led the U.S. launch of TRULANCE® (plecanatide), the first once-daily prescription therapy for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). She previously held senior roles at Salix Pharmaceuticals, including Senior Vice President of Commercial Operations and Head of the U.S. GI Business Unit, overseeing the blockbuster commercialization of XIFAXAN® (rifaximin) for hepatic encephalopathy and IBS-D, which generated billions in peak sales. At Trevi Therapeutics, Ms. Good has spearheaded the advancement of the company's lead candidate, Haduvio™ (oral naloxone), through pivotal clinical trials for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough, positioning it for potential FDA approval and commercialization. Her strategic leadership has strengthened Trevi's pipeline and financial position, earning recognition for her ability to navigate complex regulatory landscapes and deliver value to shareholders and patients alike.